ASCO 2021 Breast Cancer

T-DXd Response on Brain Mets HER2+ Breast Cancer

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...

Read More

Financial Toxicity in Women with Breast Cancer

Patients with breast cancer prioritized affordability or maintaining functional independence when making treatment decisions. Because of this variability, preference evaluation during treatment decision-making could optimize...

Read More

An Insider’s Guide to ASCO 2021: Breast Cancer

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Read More

For latest news and updates
Email-id is invalid